4.2 Article

The evaluation of adenotonsillectomy on TNF-α and IL-6 levels in obese children with obstructive sleep apnea

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijporl.2013.01.019

关键词

Adenotonsillectomy; TNF-alpha; IL-6; Obese children; OSA

向作者/读者索取更多资源

Objective: (1) To evaluate the effect of adenotonsillectomy (T&A) on clinical signs in obese children with obstructive sleep apnea (OSA); (2) to evaluate the changes in tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 levels pre- and post-surgery; and (3) to determine a potential explanation for changes in cytokine levels after T&A therapy. Subjects and methods: In brief, 90 obese children with USA were enrolled. Polysomnographic data, such as an apnea-hypopnea index (AHI) and oxyhemoglobin saturation (SaO(2)), and demographic information, such as body mass index (BMI), were collected. TNF-alpha and IL-6 levels were determined before and 6 months after T&A treatment. Results: It was observed that 61.1% of obese children with USA were persistent after T&A therapy. In general, AHI (events/h) measures decreased from 22.26 +/- 9.141 to 8.88 +/- 5.909 before and after a 6-month follow-up period, respectively, and nadir SaO(2) (%) levels increased from 74.26 +/- 7.486 to 86.37 +/- 5.578 pre- and post-surgery, respectively. However, no discernible differences in BMI measures before and after a 6month follow-up period (40.996 +/- 5.2486 vs. 40.597 +/- 5.0540) were observed. No significant differences in the TNF-alpha and IL-6 levels pre- and post-surgery were observed. TNF-alpha and IL-6 plasma levels were highly correlated with BMI measurements (TNF-alpha: r(2) = 0.2350, P < 0.001; IL-6: r(2) = 0.6629, P < 0.001). In contrast, there was no association between plasma levels and AHI measures (TNF-alpha: r(2) = 0.03377, P = 0.0829; IL-6: r(2) = 0.03946, P = 0.0605). Conclusion: T&A therapy can improve clinical symptoms and signs but is not a cure for the treatment of obese children with USA. The inflammation levels of TNF-alpha and IL-6 changed little. To reduce the risk for excessive daytime sleepiness, supplementary therapies should be introduced for USA. (C) 2013 Published by Elsevier Ireland Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据